The imbalance in osteoblast (OB)-dependent bone formation in favor of osteoclast (OC)-dependent bone resorption is the main cause of loss of tissue mineral mass during bone remodeling leading to osteoporosis conditions. Thus, the suppression of OC activity together with the improvement in the OB activity has been proposed as an effective therapy for maintaining bone mass during aging. We tested the new dietary product, KYMASIN UP containing standardized Withania somnifera, Silybum marianum and Trigonella foenum-graecum herbal extracts or the single extracts in in vitro models mimicking osteoclastogenesis (i.e., RAW 264.7 cells treated with RANKL, receptor activator of nuclear factor kappa-Β ligand) and OB differentiation (i.e., C2C12 myoblasts treated with BMP2, bone morphogenetic protein 2). We found that the dietary product reduces RANKL-dependent TRAP (tartrate-resistant acid phosphatase)-positive cells (i.e., OCs) formation and TRAP activity, and down-regulates osteoclastogenic markers by reducing Src (non-receptor tyrosine kinase) and p38 MAPK (mitogen-activated protein kinase) activation. Withania somnifera appears as the main extract responsible for the anti-osteoclastogenic effect of the product. Moreover, KYMASIN UP maintains a physiological release of the soluble decoy receptor for RANKL, OPG (osteoprotegerin), in osteoporotic conditions and increases calcium mineralization in C2C12-derived OBs. Interestingly, KYMASIN UP induces differentiation in human primary OB-like cells derived from osteoporotic subjects. Based on our results, KYMASIN UP or Withania somnifera-based dietary supplements might be suggested to reverse the age-related functional decline of bone tissue by re-balancing the activity of OBs and OCs, thus improving the quality of life in the elderly and reducing social and health-care costs.
The agri-food industry generates substantial amounts of waste, which are increasingly regarded as valuable resources within the framework of the circular economy. Among the recoverable bioactive molecules, phenolic compounds are of particular interest for nutraceutical and biomedical applications. Olive oil production by-products, such as olive oil dregs (OOD), represent a rich source of polyphenols, especially hydroxytyrosol (3,4-DHPEA). In this study, we investigated the in vitro biological properties of OOD extracts obtained through methanolic or eco-friendly aqueous extraction methods, both characterized by a high 3,4-DHPEA content. The antioxidant potential of the extracts was evaluated together with their activity in murine peritoneal macrophages, while their ability to counteract osteoclastogenesis was assessed using RAW 264.7 cells stimulated with receptor activator of nuclear factor kappa-B ligand (RANKL). Our results demonstrated that both extracts showed a total antioxidant effect and significantly reduced intracellular reactive oxygen species (ROS) levels. Notably, this antioxidant activity was accompanied by a marked inhibition of RANKL-induced osteoclast formation, as evidenced by a reduction in tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells together with fewer mature osteoclasts displaying well-structured F-actin rings and bone-resorbing activity as demonstrated by the pit formation assay. Taken together, these findings suggest that OOD extract, through its dual antioxidant and anti-osteoclastogenic properties, may represent a promising strategy for the prevention of inflammation-driven pathological bone loss.